4,7-Dibromo-5-fluoro-2,1,3-benzothiadiazole

Catalog No. :
ACLXAZ372
CAS No. :
1347736-74-6
Molecular Formula :
C6HBr2FN2S
Molecular Weight :
311.96

IUPAC Name:4,7-dibromo-5-fluorobenzo[c][1,2,5]thiadiazole

4,7-Dibromo-5-fluoro-2,1,3-benzothiadiazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$58.00Login to see priceIn stockIn stock
5g97%$191.00Login to see priceIn stockIn stock
25g97%$817.00Login to see priceIn stockIn stock
100g97%$3085.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4,7-Dibromo-5-fluoro-2,1,3-benzothiadiazole
IUPAC Name4,7-dibromo-5-fluorobenzo[c][1,2,5]thiadiazole
MDL No.MFCD26939241
Molecular FormulaC6HBr2FN2S
Molecular Weight311.96
SMILESFC1=C(Br)C2=NSN=C2C(Br)=C1
InChI KeyKVZDYOVYIHJETJ-UHFFFAOYSA-N
SynonymXDC73674 | 4,7-dibromo-5-fluorobenzo[c][1,2,5]thiadiazole | A51150 | DS-10341 | 1347736-74-6 | AMY27036 | CS-W004493 | AC-33719 | SCHEMBL2727667 | 4,7-Dibromo-5-fluoro-2,1,3-benzothiadiazole, >=99% (HPLC) | A857374 | 4,7-Dibromo-5-fluoro-benzo[1,2,5]thiad
CAS No.1347736-74-6
PubChem CID67515326

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACLXAZ372 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCVWM624 route compound structure diagram
    ACCVWM62417821-75-9 In Stock
  2. Then
  3. ACLXAZ372 route product structure diagram
    ACLXAZ3721347736-74-6 In Stock
Inquiry

2. ACLXAZ372 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCZIU451 route compound structure diagram
    ACCZIU451563-67-7 In Stock
  2. Plus
  3. ACMATR170 route compound structure diagram
    ACMATR170172377-05-8 In Stock
  4. Then
  5. ACLXAZ372 route product structure diagram
    ACLXAZ3721347736-74-6 In Stock
Inquiry

Comments (0)